5-Amino-1MQ (Capsules)

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor developed for research into metabolic regulation and cellular energy homeostasis. This compound selectively blocks NNMT enzyme activity, preventing the breakdown of nicotinamide and allowing its recycling into NAD+ through the salvage pathway. Originally developed by researchers at the University of Texas Medical Branch, 5-Amino-1MQ exhibits excellent membrane permeability and oral bioavailability due to its non-peptide structure. The compound has been investigated in preclinical models for its effects on metabolic signaling pathways, adipocyte function, and cellular redox balance. Current research examines its potential applications in metabolic dysfunction research and energy expenditure studies.

Chemical Structure and Identification

• Compound Name: 5-Amino-1-methylquinolinium (50mcg/capsule)
• Per capsule: 50 mcgs per capsule
• Molecular Formula: C₁₀H₁₁N₂
• Molecular Weight: 159.21 g/mol
• CAS Number: 42464-96-0

Research Applications

• Metabolic Regulation Research: Investigation of NNMT’s role in adipose tissue metabolism and its impact on cellular energy utilization [1]
• NAD+ Metabolism Studies: Research examining nicotinamide salvage pathways and NAD+-dependent cellular processes [2]
• Adipocyte Biology: Preclinical evaluation of white adipose tissue metabolic function and basal metabolic rate [1]
• Cellular Energy Homeostasis: Mechanistic studies of NNMT inhibition effects on mitochondrial function and ATP production [3]
• Redox Signaling: Examination of NAD+-dependent redox balance and stress response pathways [2]

Reference Citations

1. Nature Medicine (2014) – Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity | https://pubmed.ncbi.nlm.nih.gov/
2. PubMed Central (2024) – Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions | https://pmc.ncbi.nlm.nih.gov/
3. PubMed (2021) – LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study | https://pubmed.ncbi.nlm.nih.gov/
4. PubMed (2022) – Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese models | https://pubmed.ncbi.nlm.nih.gov/

Important Regulatory Notice

These products are for research use only and are not intended for human consumption, therapeutic use, or diagnostic purposes. All compounds described herein have not been approved by the FDA for human use. These products are strictly intended for in vitro laboratory research and analytical purposes when conducted by qualified research professionals in licensed facilities. Users are responsible for ensuring compliance with all applicable laws regarding purchase and use of these materials.